As the biopharmaceutical industry embraces artificial intelligence to transform clinical research, a quieter but equally powerful revolution is unfolding, one that is not driven by algorithms, but by culture.
A recent global report by Parexel, a leading clinical research organisation, reminds us that while the promise of AI is real, the main differentiator is not technology, but people.
The Human Factor in a High-Tech World
Based on the voices of 501 professionals across the U.S., Europe, and Asia-Pacific, the report captures the perspectives of both senior leaders and frontline clinical research professionals. It explores not only where AI is working, but also where talent gaps could stall its potential.
One of the report’s most compelling findings?
Top-performing organisations aren’t just adopting AI, they are cultivating cultures where continuous learning, mentorship, and purpose thrive.
As Keri Mattox, Chief Business Officer at Parexel, put it:
The best way to train people is in person. It is hands-on mentoring. The companies doing that are retaining those workers better.
In an increasingly competitive talent landscape, especially for AI-native professionals, culture is becoming a powerful retention strategy.
Also Read: 9.9% Salary Hike, 12.6% Voluntary Attrition Rate: GCCs are Rewriting the Rules on Employee Rewards
Strategic Automation: The Early Wins of AI
Despite growing interest, AI adoption across the CRO (clinical research organisation) space remains uneven. Less than 40% of respondents in Parexel’s study reported regular use of AI tools in their workflows. Yet for those who have embraced it, AI is already proving valuable in narrow but high-impact areas such as:
-
Automated clinical site reports
-
Regulatory monitoring bots
-
Real-time data synthesis in early trial phases
As Mattox was quoted on Forbes:
There are regulatory websites that won’t push updates to us. Someone had to sit and manually refresh those pages. Now, we’ve got AI bots scanning them in real time. That small automation translates into measurable acceleration when you multiply it across thousands of trials.
AI Workforce Preparedness: A Work in Progress
Parexel’s findings reveal a clear reality: the clinical research workforce is not yet ready to fully leverage AI.
-
Only 6% of executives surveyed said their organisations are “exceptionally prepared” for AI-enabled drug development.
-
A majority highlighted the training and upskilling of AI-capable talent as a top priority.
It’s not just about teaching someone how to use a tool,” Mattox explained. “It’s training people to know when that tool adds value, when it doesn’t, and how to interpret what comes out of it.
Notably, more than half of biopharma leaders expect AI expertise to be the most critical skill set needed in the next 3–5 years.
Technology Will Accelerate Trials, But People Will Define the Pace
Whether clinical operations are built on full-service outsourcing or hybrid staffing models, one truth is clear. The ability to mobilise trained, AI-literate teams will define competitive advantage. AI may be the future of clinical development, but human capability, critical thinking, and cultural alignment will determine how fast and how far we get there.
